Source: VentriPoint Diagnostics Ltd.
  • Ventripoint Diagnostics (VPT) will begin trading on the OTCQB Venture Market on January 7 under the symbol VPTDF
  • The company’s common shares will continue to trade on the TSXV under the symbol VPT
  • The OTCQB is the premier marketplace for entrepreneurial and development stage U.S. and international companies
  • Ventripoint has also applied for DTC eligibility
  • Ventripoint Diagnostics has become an industry leader in the application of AI to echocardiography
  • Ventripoint Diagnostics Ltd. (VPT) is unchanged on the day, trading at C$0.355 per share at 12:45 pm EST

Ventripoint Diagnostics (VPT) has received notification from OTC Markets to up-list to the OTCQB tier effective January 7, 2022.

The company will trade on the OTCQB exchange under the symbol VPTDF.

The company’s common shares will continue to trade on the TSXV under the symbol VPT.

Dr. George Adams, CEO of Ventripoint commented on the OTCQB listing.

“Trading on the OTCQB will enhance our visibility and make the Company accessible to a much broader range of U.S. investors and brokers. The quotation on the OTCQB will provide existing and potential investors with a transparent and easily accessible trading platform where they can find Real-Time quotes and market information.”

Shareholders of existing Ventripoint shares are not required to take any action in regards to the uplisting

The OTCQB is a US trading platform that is operated by the OTC Markets Group in New York. The OTCQB is the premier marketplace for entrepreneurial and development stage U.S. and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process.

The company has also applied for DTC eligibility.

Ventripoint Diagnostics has become an industry leader in the application of AI to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology.

Ventripoint Diagnostics Ltd. (VPT) is unchanged on the day, trading at C$0.355 per share at 12:45 pm EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.